Yves Durocher joined the NRC in 1995 and manages a section of 30 scientists involved in protein expression and CHO cell line development for internal projects and external clients. His research activities focus on improving large-scale transient gene expression (LSTGE) platforms using HEK293 and CHO cells for protein production. A special emphasis is on developing and engineering stable CHO pool and clonal cell line platforms for recombinant protein manufacturing. Yves is also an adjunct professor at the Department of Biochemistry and Molecular Medicine at the Université de Montréal.
Chinese Hamster Ovary (CHO) cells are the workhorse expression host for manufacturing glycoprotein-based therapeutics. The current pandemic has contributed to a broader acceptance from the regulatory authorities of using stable CHO pools to accelerate clinical evaluation of potentially life-saving drugs. I will present our efforts using stable CHO pools to manufacture the SARS-CoV-2 trimeric spike protein as a vaccine candidate.